Abstracts Archive - Page 2031 of 2607 - ACR Meeting Abstracts

Abstract Number: 2409 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Physical Therapy Use in Osteoarthritis of the Knee: Results from a Population-Based Study
Sicong Huang¹, Eric C. Sayre² and Jolanda Cibere^1,2, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis. Physical therapy (PT) has previously been demonstrated to benefit patients with osteoarthritis, especially with early…
Abstract Number: 2410 • 2015 ACR/ARHP Annual Meeting
Report from the International Consortium of Health Outcome Measurement Hip and Knee Osteoarthritis Working Group: Consensus on an International Standard Set of Outcomes Measures for Patients with Hip or Knee Osteoarthritis.
Philip G. Conaghan¹, Lyn March², Ola Rolfson³, Stephanie Wissig⁴, Caleb Stowell⁵, Patricia D. Franklin⁶ and The ICHOM Working Group in Hip & Knee Osteoarthritis, ¹University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ³Harris Orthopaedic Laboratory, Massachusetts General Hospital, Harvard Medical School,, International Consortium for Health Outcomes Measurement, Boston, MA, ⁴ICHOM, International Consortium for Health Outcomes Measurement, Cambridge, MA, ⁵14 Arrow St., Ste. #11, 3International Consortium for Health Outcomes Measurement, Cambridge, MA, ⁶Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To define a minimum Standard Set of outcome measures and case-mix factors for monitoring, comparing, and improving healthcare for patients with clinically diagnosed hip…
Abstract Number: 2411 • 2015 ACR/ARHP Annual Meeting
Patient Preference for Using Technology to Track and Self-Manage Osteoarthritis
Laura Khurana, Ellen Durand, Sarah Gary, Tony Otero, Chris Hall and Susan Dallabrida, ERT, Boston, MA
Background/Purpose: Active and consistent self-management is essential for patients suffering from chronic diseases to improve their health. Electronic clinical (eClinical) technology may improve how patients…
Abstract Number: 2412 • 2015 ACR/ARHP Annual Meeting
Assessment and Comparison of Responsiveness of Four Patient Reported Outcome Measures to Assess Physical Function in Patients with Knee Osteoarthritis: WOMAC-PF Subscale Responds Best
Elien A.M. Mahler¹, Nienke Cuperus², Johannes W J Bijlsma³, Thea Vliet Vlieland⁴, Frank H.J. van den Hoogen⁵, Alfons den Broeder⁵ and Cornelia H.M. van den Ende¹, ¹Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology Department, Sint Maartenskliniek, Nijmegen, Netherlands, ³Rheumatology and Clinical Immunology, ARC Amsterdam; UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Although physical function is one of the core outcome domains in knee osteoarthritis (OA), the ability of a measurement instrument to detect changes over…
Abstract Number: 2413 • 2015 ACR/ARHP Annual Meeting
Contributors to Walking Disability in People with Osteoarthritis: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) is associated with functional limitations, including difficulty walking. However, comorbid disease is common in people with OA and may also be associated…
Abstract Number: 2414 • 2015 ACR/ARHP Annual Meeting
High-Intensity Versus Low-Intensity Physical Activity or Exercises in Patients with Hip or Knee Osteoarthritis: A Meta-Analysis
Jean-Philippe Regnaux^1,2,3, Marie-Martine Lefèvre-Colau⁴, Ludovic Trinquart³, Christelle Nguyen⁵, Isabelle Boutron^1,3,6,7, Lucie Brosseau⁸ and Philippe Ravaud^3,6,7,9, ¹METHODS team, INSERM UMR-S 1153, Paris, France, ²EHESP Rennes, Sorbonne Paris Cité, Paris, France, ³French Cochrane Center, Paris, France, ⁴Univ. Paris Descartes, PRES Sorbonne Paris Cité, Service de rééducation et réadaptation de l’appareil locomoteur et des pathologies du rachis, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, Paris, France, ⁵Univ. Paris Descartes, PRES Sorbonne Paris, Cité Laboratoire de Pharmacologie, Toxicologie et Signalisation Cellulaire, INSERM UMR-S 1124, UFR Biomédicale des Saints Pères, Paris, France, Paris, France, ⁶Paris Descartes University, Sorbonne Paris Cité, Faculté de Médecine, Paris, France, ⁷Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, ⁸Rehabilitation Sciences, University of Ottawa, Ottawa, ON, Canada, ⁹METHODS team, INSERM U1153, Paris, France
Background/Purpose: Exercise or physical activity are complex interventions whose effectiveness depends on more than one component. We aimed to determine the benefits and harms of…
Abstract Number: 2415 • 2015 ACR/ARHP Annual Meeting
Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States
Karen James¹, Rui Xiao², Peter A. Merkel³ and Pamela F. Weiss¹, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare systemic vasculitidies with significant morbidity and mortality. Plasma exchange (PLEX) has been shown to decrease risk…
Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Nikolay Tzaribachev³, Zbigniew Zuber⁴, Elena Koskova⁵, Ivan Foeldvari⁶, Eizbieta Smolewska⁷, Gerd Horneff⁸, Charles Mebus⁹, Umberto Conte¹⁰, Rong Wang⁹, Christine Alvey⁹, Manisha Lamba⁹, Anasuya Hazra¹¹, Daniel Lovell¹² and Alberto Martini¹³, ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁵Institute of Rheumatic Diseases, Piestany, Slovakia, ⁶Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁷Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Collegeville, PA, ¹²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…
Abstract Number: 2417 • 2015 ACR/ARHP Annual Meeting
Induction and Maintenance of Remission By Etanercept in Enthesitis Related Arthritis JIA-Patients
Gerd Horneff¹, Ivan Foeldvari², Kirsten Minden³, Ralf Trauzeddel⁴, J B. Kuemmerle-Deschner⁵, Klaus Tenbrock⁶, Gerd Ganser⁷ and Hans-Iko Huppertz⁸, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ³DRFG, Berlin, Germany, ⁴HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁵Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁶University Aachen, Aachen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁸PRINTO, IRCCS G. Gaslini, Genoa, Italy
Background/Purpose: Enthesitis-related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category affecting entheses and joints. The REMINDER study to analyse the efficacy of etanercept (ETA)…
Abstract Number: 2418 • 2015 ACR/ARHP Annual Meeting
Pediatric Enthesitis-Related Arthritis: Variation in Disease Characteristics and Treatments Among 5 Large Centers
Sabrina Gmuca¹, Timothy Brandon², Rui Xiao³, Ilaria Pagnini⁴, Tracey B. Wright⁵, Timothy Beukelman⁶, Esi Morgan-DeWitt⁷ and Pamela F. Weiss⁸, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Paediatrics, University of Florence and Anna Meyer Children's Hospital, Florence, Italy, Florence, Italy, ⁵Pediatrics/Rheumatology, Univ of TX Southwestern, Dallas, TX, ⁶Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: We aimed to compare the clinical features and treatments of children with Enthesitis-related arthritis (ERA) from 5 pediatric rheumatology centers in order to determine…
Abstract Number: 2419 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of Etanercept in 2000 Patients with Juvenile Idiopathic Arthritis (JIA) in the JIA Biologics Register
Gerd Horneff¹, Juergen Brunner², Johannes Peter Haas³, Gerd Ganser⁴, Ivan Foeldvari⁵, Toni Hospach⁶, Kirsten Minden⁷, Hans-Iko Huppertz⁸, Rolf M. Kuester⁹, Ralf Trauzeddel¹⁰, Angelika Thon¹¹ and BIKER Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Universitätsklinik für Kinder- u. Jugendheilkunde, Innsbruck, Austria, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁵Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁶Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁷DRFG, Berlin, Germany, ⁸PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁹Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁰HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ¹¹Department of Pediatrics, Hannover, Germany
Background/Purpose: Treatment with Etanercept (ETA) was followed prospectively. The purpose of this interim analysis is to evaluate efficacy/ safety of ETA in routine care settings.…
Abstract Number: 2420 • 2015 ACR/ARHP Annual Meeting
Azathioprine for Glucocorticoid Resistant Non-Renal Henoch-Schönlein Purpura
Paul Tuttle IV¹, Peri Pepmueller² and Terry Moore³, ¹IM-Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology, Saint Louis University, St. Louis, MO, ³Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO
Background/Purpose: Henoch-Schönlein purpura is the most common small vessel vasculitis in childhood and has a classic presentation of palpable purpura. The disease is typically benign…
Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Johannes Peter Haas⁴, Toni Hospach⁵, Ralf Trauzeddel⁶, Frank Weller-Heinemann⁷, J B. Kuemmerle-Deschner⁸, Angelika Thon⁹ and BIKER study group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Rheumatology, Scleroderma, Hamburg, Germany, ⁴German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁶HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁷PRINTO, Genoa, Italy, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…
Abstract Number: 2422 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamas Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut², Katherine Marzan¹, Nico Wulffraat², Rayfel Schneider¹, Shai Padeh², Vyacheslav Chasnyk², Carine Wouters², Jasmin B. Kuemmerle-Deschner², Tilmann Kallinich², Bernard Lauwerys⁴, Elie Haddad¹, Evgeny Nasonov², Maria Trachana², Olga Vougiouka², Karolynn Leon⁵, Antonio Speziale⁶, Karine Lheritier⁶, Alberto Martini², Daniel Lovell^1,7 and on behalf of PRINTO/PRCSG, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a debilitating form of arthritis associated with systemic symptoms such as anemia, rash, leukocytosis, elevated erythrocyte sedimentation rate…
Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Nicolino Ruperto¹, Tamas Constantin², Ivan Foeldvari³, Jelena Vojinovic⁴, Gerd Horneff⁵, Rubén Burgos-Vargas⁶, Irina Nikishina⁷, Jonathan Akikusa⁸, Tadej Avcin⁹, Jeffrey Chaitow¹⁰, Elena Koskova¹¹, Bernard R. Lauwerys¹², Inmaculada Calvo-Penedes¹³, Berit Flato¹⁴, Maria Luz Gamir Gamir¹⁵, Hans-Iko Huppertz¹⁶, Juan Jose Jaller Raad¹⁷, Katerina Jarosova¹⁸, Jordi Anton¹⁹, Marie Macku²⁰, William Jose Otero Escalante²¹, Lidia Rutkowska-Sak²², Ralf Trauzeddel²³, Carine Wouters²⁴, Ronald Pedersen²⁵, Sameer Kotak²⁶, Jack F Bukowski²⁷, Tina Hinnershitz²⁸, Bonnie Vlahos²⁹ and Alberto Martini³⁰, ¹Pediatria II, PRINTO, Istituto G. Gaslini, Universita' di Genova, Genova, Italy, ²Semmelweis University, Budapest, Hungary, ³Hamburg Centre for Child and Adolescent Rheumatology, Hamburg, Germany, ⁴Faculty of Medicine, University of Nis, Nis, Serbia, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁷V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Rheumatology, Royal Children's Hospital, Melbourne, Australia, ⁹Allergology, Rheumatology and Clinical Immunology, University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁰The Sydney Children's Hospital Network, Sydney, Australia, ¹¹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹³Hospital Universitario y Piltecnico La Fe, Valencia, Spain, ¹⁴Oslo University Hospital, Oslo, Norway, ¹⁵Rheumatology, Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ¹⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ¹⁷Centro de Reumatologia y Ortopedia, Barranquilla, Colombia, ¹⁸Revmatologicky ustav, Prague, Czech Republic, ¹⁹Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ²⁰1, Facutly Children's Hospital Brno, Brno, Czech Republic, ²¹Servimed S.A.S, Santander, Colombia, ²²Instytut Reumatologii, Klinika i Poliklinika Reumatologii Wieku Rozwojowego, Warszawa, Poland, ²³HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ²⁴UZ Leuven, Leuven, Belgium, ²⁵Department of Biostatistics, Pfizer, Collegeville, PA, ²⁶Global Health and Value, Pfizer, New York, NY, ²⁷Pfizer, Collegeville, PA, ²⁸Specialty Care MDG, Pfizer, Collegeville, PA, ²⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ³⁰Istituto G. Gaslini, Universita' di Genova, Genova, Italy
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].